Procter & Gamble turns to Eagle for bioinformatics software

Posted: Published on December 10th, 2014

This post was added by Dr P. Richardson

Global consumer products giant Procter & Gamble (P&G) has turned to Cambridge bioinformatics technology to accelerate certain areas of research.

No figures are being disclosed for the four-year deal secured by Eagle Genomics, the Babraham Research Campus company.

P&Gs Global Biotechnology and Life Sciences Department will use Eagles bioinformatics software platform, eaglecore, to help accelerate research of new products, organise existing data and integrate legacy data with more recent data for analysis across the company.

The deal will see P&G take a four-year licence for an undisclosed sum, which will include additional data curation services.

The agreement follows a long partnership between Eagle and P&G involving Eagles consultancy arm, which has been used to support past research.

Dr Abel Ureta-Vidal, CEO of Eagle said: eaglecore is an extremely powerful platform and will have a major impact on P&Gs approach to their current research projects.

By using our platform, P&G will able to better reference, manage and use all of their data to develop new insights and products, saving both time and development costs.

He said eaglecore improves bioinformatics research to help accelerate the development of new products, including pharmaceuticals, consumer goods, food and beverages, livestock and crop development, and biofuels. eaglecore allows its users to integrate, tag and reference all of their research data in a single place allowing researchers to better use their data with new insights, and new developments.

P&G IP is behind household products such as Gillette razors, Pantene shampoo and Hugo Boss scent while Eagle addresses key challenges in healthcare, food and consumer goods.

PHOTOGRAPH SHOWS: Dr Abel Ureta-Vidal

Original post:
Procter & Gamble turns to Eagle for bioinformatics software

Related Posts
This entry was posted in BioInformatics. Bookmark the permalink.

Comments are closed.